Latest Updates
-
Recurring Chest Infections: Expert Explains If It Could Be a Sign of Lung Cancer? -
Solar Eclipse 2026: Date, Time And Livestream Details For India -
Cristiano Ronaldo And Georgina Rodríguez Are Married After Ten Years Together -
Hariyali Amavasya 2026: Spiritual Renewal, Ancestral Gratitude, Harmony With Nature — Astrologer’s Insights -
Hariyali Teej 2026: 7 Celebrity-Inspired Green Outfits That Deserve A Spot In Your Festive Wardrobe -
Tiranga Mountain Rescue: Inside The Mission To Save Lives In India’s Most Dangerous Terrains -
Mental Health After A Flood: Coping With Stress And Anxiety, Expert Explains -
Supriya Sule’s Daughter Revati’s Delhi Reception Draws PM Modi, Rahul Gandhi And Other Leaders Together -
Solar Eclipse 2026: Date, Visibility In India And Astrological Impact On All Moon Signs -
Dental Trouble Despite Good Oral Hygiene? A Rheumatologist Explains What It Could Mean
Each Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval

The price of Covishield and Covaxin, the COVID-19 vaccines which are expected to soon get regular market approval from India's drug regulator, is likely to be capped at Rs 275 per dose plus an additional service charge of Rs 150, official sources said. According to them, the National Pharmaceutical Pricing Authority (NPPA) has been directed to start working towards capping the price to make the vaccines affordable.
As of now, Covaxin is priced at Rs 1,200 per dose while Covishield costs Rs 780 in private facilities. The prices include Rs 150 service charge. Both the vaccines are only authorised for emergency use in the coAn Subject Expert Committee on COVID-19 of the Central Drugs Standard Control Organisation on January 19 recommended granting regular market approval to COVID vaccines Covishield and Covaxin for use in the adult population subject to certain conditions.
"The NPPA has been asked to work towards capping the price of the vaccines. The price is likely to be capped at Rs 275 per dose along with an additional service charge of Rs 150," an official source said.
Prakash Kumar Singh, the director (government and regulatory affairs) at Serum Institute of India, had submitted an application to the Drugs Controller General of India on October 25 seeking regular market approval for its Covishiled vaccine.
A couple of weeks ago, V Krishna Mohan, the whole-time director at Bharat Biotech, submitted complete information on the chemistry, manufacturing and controls, along with the pre-clinical and clinical data while seeking regular market authorisation for Covaxin.
Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.
COVID vaccine - Photo by DW News / Getty Images.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications